Abstract Library

Members may log into MY ENETS to visit the abstract library from previous ENETS conferences.

Participants of the ENETS Conference in 2022 can now access the abstract booklet, e-posters and videos, the poster carousel, and more via My ENETS.

ENETS Abstract Search

#1586 Biomarkers for Carcinoid Heart Disease

Introduction: Carcinoid heart disease (CHD) develops in patients with carcinoid syndrome. Currently NT-proBNP (NTP) is suggested as the best current biomarker to screen for CHD and monitor heart failure. A number of other markers have been investigated for heart failure.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Srirajaskanthan R

Authors: Basuroy R, Srirajaskanthan R, Ramage J, Sherwood R,

Keywords: carcinoid heart disease,

#1332 NT-proBNP is Superior to ST2 and Galectin-3 Cardiac Markers in Identifying Carcinoid Heart Disease in Small Bowel NET Patients

Introduction: Carcinoid heart disease (CHD) develops in small bowel neuroendocrine tumour (sbNET) patients with carcinoid syndrome (CS). NT-proBNP (NTP) is suggested as the best current biomarker to screen and monitor for HF from CHD. A number of other markers, such as Galectin-3 (GAL3) and ST2 (or IL-1 R4), have been explored to diagnose and prognosticate in HF but have not been explored in NET patients with CS and CHD.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author:

Authors: Basuroy R, Srirajaskanthan R, Ramage J, Sherwood R,

Keywords: Carcinoid Heart Disease, Biomarker,

#1177 An Isolated Abnormal Chromogranin B Is Associated with Pancreato-Duodenal NETs and the Presence of Liver Metastases

Introduction: Chromogranin B (CgB) is a soluble secretory protein like chromogranin A (CgA) that has been reported to be elevated in patients with neuroendocrine tumours (NETs) but is not routinely assessed.

Conference: 12th Annual ENETSConcerence (2015)

Presenting Author:

Authors: Basuroy R, Sherwood R, Srirajaskanthan R, Ramage J,

Keywords: chromogranin A, chromogranin B, pancreas, duodenal, assay, liver metastases,

#684 Clinical Characteristics and Survival of Neuroendocrine Tumors of Unknown Primary

Introduction: NETs of unknown primary account for 10-15% of NETs. There is limited published literature on this group of NETs.

Conference: 10th Annual ENETSConcerence (2013)

Presenting Author: Srirajaskanthan R

Authors: Srirajaskanthan R, Quaglia A, Vivian G, Mulholland N, Sherwood R,

Keywords: unknown primary, survival ,

Abstract Submissions in 2023

Abstract submissions for 2023 will open in September 2022!

 

The 20th Annual ENETS Conference in 2023 will provide the principal platform for NET researchers around the world to present their latest findings. ENETS will select the best abstracts submitted in both clinical and basic science and present these in sessions within the framework of its scientific programme.

 

Participants of the ENETS Conferences in 2022 can now access the abstract booklet, e-posters and videos, the poster carousel, and more via My ENETS.

Membership matters

Multidisciplinary is our credo. We welcome all NET-related disciplines and professionals! Learn more about the benefits of becoming an ENETS member.